Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 80 NHL: R-DHAP + high-dose methotrexate with intrathecal rituximab followed by autologous stem cell transplantation in recurrent aggressive B-cell lymphoma with CNS involvement
NL-OMON37237Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Oct 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, methotrexate, cisplatin, cytarabine and dexamethasone in mature B-cell lymphoma, central nervous system lymphoma and non-Hodgkin lymphoma (NHL), sponsored by HOVON. Primary endpoints: Feasibility of treatment and Efficacy (tumor response and survival). Started Oct 2006; status: recruiting.
02
Drugs
rituximabmethotrexatecisplatincytarabinedexamethasone
03
Conditions
mature B-cell lymphomacentral nervous system lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NL-OMON37237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37237.